Business Wire

Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023

COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today presented ...
Medscape

Percutaneous administration of cell and gene therapy show increased cardiac function

In a late-breaking trial presentation, Dr Jens Kastrup (University Hospital Rigshospitalet, Copenhagen, Denmark) presented the results from the Euroinject One trial of gene therapy for patients with ...
Business Wire

Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first patients have ...
BioWorld

Fast-acting and reversible: Basking seeks to expand options in ischemic stroke

Acute thrombosis, including heart attack and stroke, is a leading cause of mortality worldwide. Yet only a small fraction of patients can be treated with current therapeutic or surgical interventions.